Competitor Analysis: Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017
This Competitive Intelligence report about Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017 provides a competitor evaluation in the field of antibodies, vaccines and engineered chimeric antigen receptor (CAR) T-cells targeting mesothelin as of August 2017.
Mesothelin is a surface marker protein overexpressed in many cancers and is a suitable target for directing immunotherapeutics to mesothelin expressing tumors, such as malignant pleural mesothelioma, mesothelioma and pancreatic, non-small cell lung, ovarian, endometrial and gastric cancers.
The report includes a compilation of currently active projects in research and development of antibodies, vaccines and engineered T-cells directed against mesothelin. In addition, the report lists company- and institution-specific R&D pipelines of anti-Mesothelin Immunotherapeutics. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Mesothelin is a surface marker protein overexpressed in many cancers and is a suitable target for directing immunotherapeutics to mesothelin expressing tumors, such as malignant pleural mesothelioma, mesothelioma and pancreatic, non-small cell lung, ovarian, endometrial and gastric cancers.
The report includes a compilation of currently active projects in research and development of antibodies, vaccines and engineered T-cells directed against mesothelin. In addition, the report lists company- and institution-specific R&D pipelines of anti-Mesothelin Immunotherapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1) Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017
- Mesothelin-Targeted Antibodies
- Mesothelin-Targeted Vaccines
- Mesothelin-Targeted Engineered CAR T-Cells
More Publications
Protein Target & Pipeline Database: 1-Year Subscription
US$ 1,588.00
July 2013
-
The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry
US$ 1,920.00
October 2013
84 pages
Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis
US$ 1,203.00
March 2013
88 pages
